Exelixis (EXEL) Financials: History & Chart

Exelixis, Inc.(EXEL)

Biotechnology · Alameda, CA

$58.85+0.46 (+0.79%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Exelixis, Inc.

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Alameda, CA

1,077 employees

www.exelixis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Morrissey

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jul 2026	Quarter ended Apr 2026	Quarter ended Jan 2026	Quarter ended Oct 2025	Quarter ended Jul 2025	Quarter ended Apr 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	2.44B	628.69M	610.81M	598.66M	597.75M	568.26M	555.45M	566.75M	539.54M
Cost of Goods Sold	85.67M	20.66M	19.95M	26.48M	18.57M	19.47M	19.17M	19.96M	17.33M
Gross Profit	2.35B	608.03M	590.86M	572.18M	579.18M	548.79M	536.27M	546.79M	522.21M
Gross Profit Margin	96.5%	96.7%	96.7%	95.6%	96.9%	96.6%	96.5%	96.5%	96.8%
Total Operating Expenses	1.38B	359.62M	339.52M	336.97M	342.64M	335.21M	349.42M	383.58M	386.14M
Research & Development	824.32M	211.99M	199.92M	213.25M	199.16M	200.36M	212.23M	249.00M	222.57M
Selling, General & Administrative	533.92M	147.63M	139.60M	123.02M	123.66M	134.86M	137.18M	134.33M	111.80M
Operating Income (EBIT)	971.51M	248.41M	251.34M	235.22M	236.54M	213.58M	186.86M	163.21M	136.07M
Operating Margin	39.9%	39.5%	41.1%	39.3%	39.6%	37.6%	33.6%	28.8%	25.2%
Income Before Tax (EBT)	1.04B	262.68M	267.69M	252.69M	252.41M	230.41M	205.69M	184.77M	154.75M
Interest Income	63.69M	14.21M	16.13M	17.43M	15.92M	16.79M	19.08M	21.30M	18.71M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	63.95M	14.26M	16.35M	17.47M	15.87M	16.84M	18.83M	21.57M	18.68M
Net Income	860.62M	212.05M	210.47M	244.53M	193.58M	184.85M	159.62M	139.86M	117.97M
Income Tax Expense	174.84M	50.63M	57.22M	8.16M	58.84M	45.57M	46.07M	44.91M	36.78M
Net Profit Margin	35.3%	33.7%	34.5%	40.8%	32.4%	32.5%	28.7%	24.7%	21.9%
EBITDA	999.81M	255.40M	258.29M	242.16M	243.96M	220.92M	194.20M	170.85M	143.53M
EBITDA Margin	41.0%	40.6%	42.3%	40.5%	40.8%	38.9%	35.0%	30.1%	26.6%
Depreciation & Amortization	28.30M	6.98M	6.95M	6.95M	7.42M	7.34M	7.34M	7.64M	7.45M
EPS Basic	3.29	0.85	0.81	0.91	0.72	0.68	0.57	0.48	0.41
EPS Diluted	3.19	0.82	0.79	0.88	0.70	0.65	0.55	0.47	0.40
Weighted Average Basic Shares	250.81M	250.81M	258.33M	271.57M	268.42M	272.58M	278.80M	284.53M	285.62M
Weighted Average Diluted Shares	259.68M	259.68M	267.32M	281.86M	278.54M	284.39M	288.18M	293.55M	291.48M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	01/02/2026	01/03/2025	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	2.32B	2.17B	1.83B	1.61B	1.43B	987.54M	967.77M	853.83M
Cost of Goods Sold	83.70M	76.22M	72.55M	57.91M	52.87M	36.27M	33.10M	26.35M
Gross Profit	2.24B	2.09B	1.76B	1.55B	1.38B	951.27M	934.68M	827.48M
Gross Profit Margin	96.4%	96.5%	96.0%	96.4%	96.3%	96.3%	96.6%	96.9%
Total Operating Expenses	1.36B	1.49B	1.59B	1.35B	1.10B	841.21M	565.21M	388.62M
Research & Development	825.00M	910.41M	1.04B	891.81M	693.72M	547.85M	336.96M	182.26M
Selling, General & Administrative	518.73M	492.13M	542.71M	459.86M	401.71M	293.36M	228.24M	206.37M
Operating Income (EBIT)	872.19M	604.62M	170.88M	201.48M	286.67M	110.06M	369.47M	438.86M
Operating Margin	37.6%	27.9%	9.3%	12.5%	20.0%	11.1%	38.2%	51.4%
Income Before Tax (EBT)	941.21M	681.64M	257.52M	234.35M	294.15M	130.84M	398.11M	452.09M
Interest Income	69.21M	77.16M	86.54M	33.06M	7.67M	19.86M	27.96M	12.84M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	69.02M	77.02M	86.64M	32.87M	7.49M	20.78M	28.64M	13.24M
Net Income	782.57M	521.27M	207.76M	182.28M	231.06M	111.78M	321.01M	690.07M
Income Tax Expense	158.64M	160.37M	49.76M	52.07M	63.09M	19.06M	77.10M	-237.98M
Net Profit Margin	33.7%	24.0%	11.4%	11.3%	16.1%	11.3%	33.2%	80.8%
EBITDA	901.25M	633.42M	196.60M	222.36M	300.30M	119.20M	380.64M	443.77M
EBITDA Margin	38.8%	29.2%	10.7%	13.8%	20.9%	12.1%	39.3%	52.0%
Depreciation & Amortization	29.05M	28.80M	25.72M	20.88M	13.63M	9.14M	11.17M	4.92M
EPS Basic	2.88	1.80	0.65	0.57	0.73	0.36	1.06	2.32
EPS Diluted	2.78	1.76	0.65	0.56	0.72	0.35	1.02	2.21
Weighted Average Basic Shares	271.57M	290.03M	318.15M	321.53M	314.88M	308.27M	302.58M	297.89M
Weighted Average Diluted Shares	281.86M	296.13M	321.46M	324.56M	322.36M	318.00M	315.01M	312.80M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.